Eli Lilly entered the week having strengthened its lead in a rapidly growing field of obesity treatments, after publishing more granular clinical data for retatrutide, a once-weekly injectable now in development. The trial details presented last weekend reinforced expectations among clinicians and market participants that retatrutide could deliver the deepest weight reductions of any therapy currently available or under evaluation.
The concentrate of new trial data at the American Diabetes Association meeting in New Orleans turned the conference into an event focused heavily on weight loss, as Roche, AstraZeneca, Pfizer, Novo Nordisk, Zealand Pharma and others disclosed fresh results or updates on their experimental medicines. Market commentary following the presentations emphasized expanding choice for patients, but also suggested that many contenders are broadly comparable to existing agents on efficacy and adverse events, while Lilly’s forthcoming medicines are widely viewed as setting a higher bar.
RBC analyst Trung Huynh summarized that view succinctly, saying that drugs shown by Novo, Roche and other groups are "on par" with current therapies in both weight loss and side-effect profiles but cannot yet match the capabilities expected from Lilly’s next-generation portfolio. "The bar is just moving higher and higher," he said.
Market moves after the conference reflected that dynamic. Eli Lilly shares closed the first trading day after the event up 1.6%. By contrast, the report notes that Novo Nordisk shares fell by 4.2%, and Roche, Pfizer and Zealand Pharma also gave up ground following the presentations.
Segmentation and positioning
Industry participants and company executives framed the emerging field as one that will segment rather than converge on a single therapeutic approach. Roche said patients seeking maximum weight loss may gravitate toward more potent dual-acting drugs such as enicepatide, while others may prioritize a smaller but more tolerable degree of loss if that improves the likelihood of staying on therapy.
Manu Chakravarthy, who leads cardiovascular, renal and metabolism product development at Roche, emphasized the heterogeneity of people living with obesity and the need to consider the full range of patient profiles. In mid-stage data Roche presented at the conference, patients receiving enicepatide lost an average of 22.7% of bodyweight, and the company reported a gastrointestinal side-effect profile similar to existing GLP-1 medicines.
Roche also highlighted petrelintide, an amylin-based agent administered once weekly, noting it appears to have a "placebo-like" tolerability profile that could offer an advantage for patients sensitive to gastrointestinal effects.
AstraZeneca identified an oral GLP-1 candidate, elecoglipron, as a potential foundation for a broader obesity strategy that could include combination approaches with medicines already used for type 2 diabetes, kidney disease and cardiovascular conditions.
Both Novo Nordisk and Lilly framed their strategies around offering multiple options across a broad market. Novo’s chief medical officer, Filip Knop, said the company seeks to match the right medicine to the right patient rather than adopting a one-size-fits-all strategy. Lilly’s cardiometabolic head, Kenneth Custer, made a similar point about providing a range of choices; he said patients "may even choose to start on one Lilly medicine and move to another Lilly medicine."
Tolerability remains the key unmet need
Across the presentations, tolerability emerged as an area with the most room for improvement. Therapies that act on the GLP-1 and GIP hormonal pathways commonly produce gastrointestinal side effects such as nausea and vomiting. Clinical-trial discontinuation rates tied to side effects have become a closely watched metric among investors and clinicians.
Studies cited at the meeting indicate that roughly 40% of patients on some of these drugs experience nausea. That degree of gastrointestinal impact has motivated companies to pursue molecules or combinations that preserve efficacy while reducing side effects.
Pfizer reported data on berobenatide, an investigational agent whose side-effect profile Pfizer said is similar to Novo Nordisk’s Wegovy. Pfizer noted the potential for berobenatide to be administered as a monthly injection, which would be a different dosing cadence from many weekly options.
HSBC analyst Rajesh Kumar commented that tolerability is the principal unmet need at present. He suggested that for many patients, weight losses over 12% to 15% are sufficient and that most do not require losses above 20%. In his framing, an ideal therapy combines competitive efficacy with good tolerability and a regimen patients can sustain.
Several companies, including Lilly, Pfizer, AbbVie, AstraZeneca and Roche working with Zealand Pharma, are developing amylin-based drugs with the hope these will offer improved tolerability compared with GLP-1 and GIP combinations.
Not all efforts succeeded in exceeding expectations. Novo’s combination candidate Cagrisema, which pairs semaglutide with an amylin agent and was discussed as a potential successor to Wegovy, fell short of weight-loss expectations presented to the meeting.
Lilly’s eloralintide is another amylin-pathway product positioned to address tolerability concerns. Kenneth Custer noted the amylin class has "stood out" so far for its tolerability profile and said Lilly aims to ensure that the minority of patients who prefer alternative tolerability or efficacy trade-offs have options to choose from.
Implications for markets and healthcare segments
The conference presentations underscore that commercial and clinical competition in obesity therapeutics is intensifying. Market segmentation by efficacy and tolerability could shape prescribing patterns, patient adherence, and the competitive positioning of major pharmaceutical firms. Investors and healthcare stakeholders will watch both efficacy outcomes and tolerability measures closely as companies advance these candidates through later-stage trials.
Reporting on clinical trial details and market reaction at a major diabetes meeting showed how companies are differentiating their pipelines while Lilly’s retatrutide data reinforced its role as the benchmark for next-generation weight-loss therapies.